Our History

Key stages in Guerbet’s recent development

Guerbet History

As a real-life family success story, the Guerbet company has been contributing for nearly a century to the major pharmaceutical discoveries that fuel progress in medical imaging.

Guerbet acquires Accurate Medical Therapeutics

An innovative company that develops microcatheters for Interventional Imaging.

Guerbet invests in the Truffle Capital fund

With the objective to contribute to the development of therapeutic solutions that are very innovative for the health of patients, particularly those based on minimally invasive, ambulatory or image-guided procedures.

Guerbet launches Vectorio®, an innovative medical device for Interventional Imaging.

In Diagnostic Imaging, Guerbet enriches its integrated offer with new Digital Services (Contrast&Care®…).

Acquisition of Mallinckrodt's contrast media and delivery systems business

Guerbet announces on November 27 that it has acquired Mallinckrodt’s contrast media and delivery systems business (“CMDS”). With this acquisition, Guerbet aims to create a new global leader in medical imaging.

Find out more

Launch of FlowSens®, new generation injection solution in CT imaging

FlowSens® and its associated disposables are designed to fit seamlessly into the organization of radiology services. Ergonomic and easy-to-use, FlowSens® aims at meeting the practical requirements of radiologists and radiographers.

Composed of a soft bag injector, a complete range of associated disposables and services, the FlowSens® solution is the only one on the market which combines a hydraulic syringe-free injection system with intuitive usage and safeguarding of procedures at every stage of the injection. FlowSens® is compatible with ScanBag® and all types of contrast agent available on the market.

Dotarem® and Lipiodol®

FDA Approves Dotarem®, first macrocyclic and ionic gadolinium-based contrast agent in USA and Grants Orphan Drug Designation to Lipiodol® for Patients with Hepatocellular Carcinoma.

Yves L'Epine CEO

Following the death of Bernard Massiot, CEO of the Guerbet group, Yves L'Epine is appointed as the CEO.

Appointment of Bernard Massiot

The Supervisory Board of Guerbet that met on Monday, 11 January, under the chairmanship of Jean-Jacques Bertrand, appointed Bernard Massiot as chairman of the Executive Board of Guerbet, replacing Philippe Decazes. His appointment is destined to provide new momentum to the Group in achieving its objective of becoming a major player in the medical imaging sector.

An international dimension

After opening three new European affiliates in Spain, in Switzerland (1987) and Austria (1996), and launching Guerbet Spa in Italy (2000), Guerbet continues its international expansion by strengthening its presence in Asia. Its Japanese affiliate, which opened in 1978, is followed by others in South Korea (1998), Hong-Kong (2000) and Taiwan (1999). In 2002 Guerbet also becomes established in the USA.
As part of its growth strategy, Guerbet acquires Medex Biomedical in 2004 and in 2005 signs a distribution deal with Terumo Corp in Japan.

Its product portfolio is further supplemented by the re-acquisition in 2002 of global rights for Oxilan® in X-ray imaging and the launch in 2003 of Artirem® for MRI (intra-articular imaging).

End of 2006, Guerbet launches a dual Xenetix® innovation with a polypropylene softbag (ScanBag® by Xenetix®) and its associated injector (SBI 5002-CT® by Medex).

Bolstered MRI product range and continued pan-European construction

Guerbet continues its European growth by opening affiliates in Germany (1992), the UK and Turkey (1994). At the same time it bolsters its MRI portfolio with new products: Lumirem® in MRI (1993), Xenetix® in X-ray imaging (1994) and Endorem® in MRI (1995)

An international dimension

Guerbet kicks off its international expansion by opening its first affiliate in Brazil in 1972. Guerbet strengthens its production capabilities by building a second chemical plant in Lanester (Morbihan) in 1981 and acquiring Simafex (fine chemicals) in 1987.
Guerbet markets Hexabrix® in France (1979), the USA and Japan (1985) while continuing to innovate by launching Dotarem® for MRI in 1989 in France. Another major event in this period of expansion is Guerbet's introduction on the second market of the Paris Bourse.

Research and consolidation

In 1964 Michel Guerbet takes over from his father André at the top of the laboratory. 1964 is also marked by the discovery of Telebrix®.
In 1968 Guerbet moves to Aulnay-sous-Bois and in 1979 adds Hexabrix® to its range of X-ray imaging products.

Birth of the Laboratory

Foundation of the André Guerbet and Co Laboratory.
In 1927, Guerbet moves to Saint-Ouen. Marcel Guerbet and his son André push hard for initiatives in research, innovation and industrial and commercial business practices. New contrast agents are used in urography and angiography, bronchography and hysterosalpingography.

Invention of Lipiodol®

Marcel Guerbet develops an iodized oil called Lipiodol®. Its opacifying properties, discovered in 1918, will make it the world's first iodized contrast agent.